Oireachtas Joint and Select Committees

Wednesday, 21 November 2018

Joint Oireachtas Committee on Health

Evaluating Orphan Drugs: Discussion (Resumed)

9:00 am

Professor Michael Barry:

It is simply because of timing and the point at which they were presented to us. Kuvan was dealt with first and then we moved on to Spinraza. There is no reason other than that. It is just a question of-----

Comments

No comments

Log in or join to post a public comment.